GlassScriptPhysician profile
Yasmin Anwar
NPI 1588602247
$7,951.97
in general payments reported to CMS, 2019-2025
27 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,406 · 2022: $1,865 · 2023: $1,518 · 2024: $1,963 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,215 · Education: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,215.16 |
| Education | $465.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,123.05 | 2021-2025 | |
| Janssen Biotech, INC. | $663.93 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Genzyme Corporation | $648.17 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $642.63 | 2021-2025 | Ilumya |
| Amgen INC. | $573.49 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $553.65 | 2021-2025 | Adbry, Spevigo |
| Incyte Corporation | $482.35 | 2021-2024 | Opzelura |
| Pfizer INC. | $470.39 | 2021-2025 | |
| Galderma Laboratories, L.P. | $457.66 | 2021-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $390.07 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $353.14 | 2024-2025 | Dupixent |
| Almirall LLC | $303.71 | 2021-2023 | Klisyri |
| Dermavant Sciences, INC. | $226.10 | 2023-2024 | Vtama |
| Ucb, INC. | $217.89 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $183.20 | 2022-2024 | Taltz, Olumiant, Zepbound |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $131.29 | 2022-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.93 | 2023-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $72.43 | 2021-2024 | Duobrii, Siliq |
| Arcutis Biotherapeutics, INC. | $72.27 | 2023-2024 | Zoryve |
| Janssen Scientific Affairs, LLC | $60.00 | 2022 | |
| Organon LLC | $51.36 | 2025 | Vtama |
| Boston Scientific Corporation | $49.11 | 2023 | Wavewriter Alpha Prime 16 |
| Verrica Pharmaceuticals INC. | $41.59 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $40.26 | 2021 | |
| Krystal Biotech INC | $25.21 | 2023 | Vyjuvek |
| Strata Skin Sciences, INC. | $16.30 | 2021 | |
| Biofrontera INC. | $14.79 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasmin Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.